BAX

Baxter International Inc. 2025 Annual Report (10-K) Summary

Business Context and Reporting Period

This filing covers the fiscal year ended December 31, 2025. Baxter International Inc. is a global medical technology company operating in three reportable segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. The reporting period reflects the company's transition following the sale of its Kidney Care business (now Vantive Health LLC) in January 2025. The company operates in over 100 countries with approximately 37,500 employees globally.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 6% on a reported basis and 3% on an operational basis. International sales grew 7% (reported), while U.S. sales grew 5% (reported).
• Profitability Decline: The company reported a net loss of $957 million, widening from a $649 million loss in 2024. This was driven by $2.09 billion in special items, including goodwill impairments, asset impairments, and restructuring costs.
• Margin Compression: Gross margin decreased 7.4 percentage points to 30.1%, impacted by special items (9.2 pts), product mix, tariffs, and the Novum LVP recall.
• Debt Reduction: Total debt decreased by approximately $3.65 billion. The company repaid $3.81 billion of legacy indebtedness in 2025, primarily using proceeds from the Kidney Care sale.
• Dividend Reduction: In November 2025, the quarterly dividend was reduced to $0.01 per share to support deleveraging efforts.

Guidance, Outlook, and Risks

Management Commentary & Strategy:

• Deleveraging: The primary strategic focus is achieving a net leverage target of approximately 3.0x by the end of 2026. The company intends to continue paying dividends but will not conduct share repurchases during this period.
• Leadership Transition: Andrew Hider was appointed President and CEO in July 2025. The company is streamlining operations and eliminating managerial layers.
• Capital Allocation: Proceeds from the Kidney Care sale ($3.3 billion net after-tax) were used to repay debt. The company remains highly selective regarding acquisitions.

• Novum LVP Recall: A Class I recall for the Novum IQ Large Volume Pump resulted in a voluntary ship and installation hold in the U.S. and Canada. The company recorded approximately $105 million in reserves for sales reductions, returns, and remediation costs.
• Goodwill Impairments: A $485 million goodwill impairment was recorded for the Front Line Care reporting unit due to lower forecasted operating results and higher discount rates.
• Intangible Asset Impairment: A $290 million impairment was recorded for the Welch Allyn trade name.
• Hurricane Helene: The company incurred $133 million in pre-tax charges related to damages and remediation at its North Cove facility, impacting IV solutions demand.
• Tax Matters: The effective tax rate was (78.2)% due to increased reserves for uncertain tax positions (approx. $280 million related to IRS transfer pricing audits) and valuation allowances.

Investor Verification Checklist

• Novum LVP Resolution: Verify the timeline for lifting the ship and installation hold and the potential for additional remediation costs beyond the $105 million reserve.
• Deleveraging Progress: Monitor quarterly debt repayments to assess the feasibility of reaching the 3.0x net leverage target by end of 2026.
• Tax Audit Outcome: Track the status of the IRS transfer pricing examination regarding Costa Rica and Puerto Rico operations, which has led to significant tax reserves.
• IV Solutions Demand: Assess whether fluid conservation practices by customers (post-Hurricane Helene) have permanently reset demand levels for IV solutions.
• Front Line Care Performance: Review operational metrics for the Front Line Care unit to determine if the goodwill impairment reflects a structural decline or temporary market conditions.